Science Current Events | Science News | Brightsurf.com
 

Nursing home residents at heightened risk of falling in the days following

July 18, 2011
Increased surveillance over 48-hour period may decrease falls

BOSTON-Nursing home residents taking certain antidepressant medications are at an increased risk of falling in the days following the start of a new prescription or a dose increase of their current drug, according to a new study by the Institute for Aging Research of Hebrew SeniorLife, an affiliate of Harvard Medical School.

Published online in the Journal of Gerontology: Medical Sciences, the study found that nursing home residents have a fivefold increased risk of falling within two days of a new prescription for or an increased dose of a non-SSRI (selective serotonin reuptake inhibitor) antidepressant such as bupropion or venlafaxine. The findings suggest that nursing home staff should closely monitor these residents following a prescription change to prevent potential falls.

"Our results," says lead author Sarah D. Berry, M.D., M.P.H., a scientist at the Institute for Aging Research, "identify the days following a new prescription or increased dose of a non-SSRI antidepressant as a window of time associated with a particularly high risk of falling among nursing home residents."

The risk of falls, she says, may be due to acute cognitive or motor effects that have not yet been fully investigated. Certain non-SSRIs, such as trazodone, can cause postural hypotension, a dramatic decrease in blood pressure upon standing that may contribute to falls. Other non-SSRIs, like venlafaxine, can cause sedation and coordination problems that may lead to falls.

According to some estimates, more than one-third of the country's nearly 1.6 million nursing home residents take some type of antidepressant medication. Several previous studies have implicated antidepressants, including both SSRIs, such as paroxetine and sertraline, and non-SSRIs, as a risk factor for falls, especially among older adults; however, it is unclear if the risk accrues during the duration of use or if there are acute risks associated with the initiation or change in dose of a prescription.

Both tricyclic antidepressants and SSRIs, the most commonly prescribed antidepressant medications, have been associated with up to a sixfold increased risk of falls among nursing home residents in other studies. Newer drugs, including serotonin-norepinephrine reuptake inhibitors, may also be associated with falls risk. Regardless, says Dr. Berry, "these drugs are effective at treating the symptoms of depression, and many clinicians are reluctant to withhold their use based solely on a risk for falls."

Although many studies have examined chronic antidepressant use as a risk factor for falls, few have considered the short-term effects of a change in antidepressant prescription. Dr. Berry's study, called a case-crossover study, examined 1,181 residents of a Boston-area nursing home who fell, comparing the frequency of antidepressant changes during a "hazard" period (1-7 days before a fall) with the frequency of antidepressant changes during a control period (8-14 days before a fall). Information on falls was collected using the facility's federally-mandated computerized incident reports. The risk of falls was greatest within a two-day period of a change in a non-SSRI prescription (either new or existing), while no association was found between SSRIs and falls. The risk of falls diminished each day following the prescription change.

In light of her findings, says Dr. Berry, an instructor in medicine at Harvard Medical School, "nursing home staff should keep a watchful eye on residents in the days following a non-SSRI antidepressant change to prevent falls and clinicians should avoid making changes on weekends or during times when unfamiliar staff is present."

###

The study was funded by a grant from the National Institute on Aging, the Hartford Geriatrics Health Outcomes Research Scholars Awards Program, and the Men's Associates of Hebrew SeniorLife.

Scientists at the Institute for Aging Research seek to transform the human experience of aging by conducting research that will ensure a life of health, dignity and productivity into advanced age. The Institute carries out rigorous studies that discover the mechanisms of age-related disease and disability; lead to the prevention, treatment and cure of disease; advance the standard of care for older people; and inform public decision-making.

Founded in 1903, Hebrew SeniorLife, an affiliate of Harvard Medical School, is a nonprofit, nonsectarian organization devoted to innovative research, health care, education and housing that improves the lives of seniors. For more information, please visit www.hebrewseniorlife.org.

Hebrew SeniorLife Institute for Aging Research


Related Antidepressant Current Events and Antidepressant News Articles


Scientists discover 'dimmer switch' for mood disorders
Researchers at University of California, San Diego School of Medicine have identified a control mechanism for an area of the brain that processes sensory and emotive information that humans experience as "disappointment."

Single dose of antidepressant changes the brain
A single dose of antidepressant is enough to produce dramatic changes in the functional architecture of the human brain. Brain scans taken of people before and after an acute dose of a commonly prescribed SSRI (serotonin reuptake inhibitor) reveal changes in connectivity within three hours.

Dopamine replacement associated with impulse control increase in early Parkinson's
New Penn Medicine research shows that neuropsychiatric symptoms such as depression, anxiety and fatigue are more common in newly diagnosed Parkinson's disease (PD) patients compared to the general population.

Researchers find potential new predictor of stress-related illnesses
Scientists studying depression in teens have discovered that subtle changes in a gene can predict how the brain reacts to stress, which can cause such health issues as depression, post-traumatic stress disorder and obesity.

Low Strength Brain Stimulation May Be Effective for Depression
Brain stimulation treatments, like electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS), are often effective for the treatment of depression. Like antidepressant medications, however, they typically have a delayed onset. For example, a patient may receive several weeks of regular ECT treatments before a full response is achieved.

Performance improvement program helps doctors better manage depression, reports journal of psychiatric practice
A performance improvement initiative for physicians can significantly increase their use of evidence-based practices in screening for and treating depression, in the July Journal of Psychiatric Practice.

Antidepressant use during pregnancy may lead to childhood obesity and diabetes
Women who take antidepressants during pregnancy may be unknowingly predisposing their infants to type 2 diabetes and obesity later in life, according to new research from McMaster University.

Fatty liver is linked to maternal use of the SSRI antidepressant fluoxetine
Adult offspring of mothers who used fluoxetine, a common antidepressant, during pregnancy were more likely to develop a fatty liver, a new animal study has found.

Tiny Molecule Could Help Diagnose and Treat Mental Disorders
According to the World Health Organization, such mood disorders as depression affect some 10% of the world's population and are associated with a heavy burden of disease.

Researchers identify new compound to treat depression
There is new hope for people suffering from depression. Researchers have identified a compound, hydroxynorketamine (HNK), that may treat symptoms of depression just as effectively and rapidly as ketamine, without the unwanted side effects associated with the psychoactive drug.
More Antidepressant Current Events and Antidepressant News Articles

The Anti-Depressant Fact Book: What Your Doctor Won't Tell You About Prozac, Zoloft, Paxil, Celexa, and Luvox

The Anti-Depressant Fact Book: What Your Doctor Won't Tell You About Prozac, Zoloft, Paxil, Celexa, and Luvox
by Peter R. Breggin (Author)


Known as "the Ralph Nader of psychiatry," Dr. Peter Breggin has been the medical expert in countless court cases involving the use or misuse of psychoactive medications. This unusual position has given him unprecedented access to private pharmaceutical research and correspondence files, information from which informs this straight-talking guide to the most prescribed and controversial category of American drugs: antidepressants. From how these drugs work in the brain to how they treat (or don't treat) depression and obsessive-compulsive, panic, and other disorders; from the documented side and withdrawal effects to what every parent needs to know about antidepressants and teenagers, The Anti-Depressant Fact Book is up-to-the minute and easy-to-access. Hard-hitting and enlightening, every...

The Antidepressant Solution: A Step-by-Step Guide to Safely Overcoming Antidepressant Withdrawal, Dependence, and "Addiction"

The Antidepressant Solution: A Step-by-Step Guide to Safely Overcoming Antidepressant Withdrawal, Dependence, and "Addiction"
by M.D. Joseph Glenmullen M.D. (Author)


With the FDA's warning that antidepressants may cause agitation, anxiety, hostility, and even violent or suicidal tendencies, these medications are at the forefront of national legal news. Harvard physician Joseph Glenmullen has led the charge to warn the public that antidepressants are overprescribed, underregulated, and, especially, misunderstood in their side and withdrawal effects. Now he offers a solution!

More than twenty million Americans -- including over one million teens and children -- take one of today's popular antidepressants, such as Paxil, Zoloft, or Effexor. Dr. Glenmullen recognizes the many benefits of antidepressants and prescribes them to his patients, but he is also committed to warning the public of the dangers associated with overprescription. Dr....

Taking Antidepressants: Your Comprehensive Guide to Starting, Staying On, and Safely Quitting

Taking Antidepressants: Your Comprehensive Guide to Starting, Staying On, and Safely Quitting
by Michael Banov (Author)


Walks readers with depression through a personalized process to help them make the right choice about starting, staying on, and stopping antidepressants.

The Antidepressant Survival Guide: The Clinically Proven Program to Enhance the Benefits and Beat the Side Effects of Your Medication

The Antidepressant Survival Guide: The Clinically Proven Program to Enhance the Benefits and Beat the Side Effects of Your Medication
by Robert J. Hedaya (Author)


"Now patients can have the best of both worlds -- freedom from depression and freedom from side effects. Dr. Robert Hedaya offers a wealth of wisdom drawn from years of clinical experience, research, and teaching. This book is a much-needed lantern in the darkness."
-- Norman Rosenthal, M.D., author of St. John's Wort: The Herbal Way to Feeling Good

* Restore the vital vitamins, minerals, and hormones necessary to maintain good health.
* Optimize your body's metabolic system.
* Restore your ability to experience pleasure in life.

An estimated twenty-five million Americans take antidepressants to combat depression, but most continue to cope with a host of debilitating side effects that equal, and sometimes outweigh, the medication's obvious benefits. Many doctors...

Antidepressants and Antianxiety Drugs (Understanding Drugs)

Antidepressants and Antianxiety Drugs (Understanding Drugs)
by Alan Hecht (Author), David J. Triggle (Editor)


Examines the history, development, biology, medical effects, and cultural impact of antidepressants and antianxiety drugs.
Title: Antidepressant and Antianxiety Drugs
Author: Hecht, Alan/ Triggle, David J. (EDT)
Publisher: Facts on File
Publication Date: 2010/11/01
Number of Pages: 108
Binding Type: LIBRARY
Library of Congress: 2010029224

Side Effects: A Prosecutor, a Whistleblower, and a Bestselling Antidepressant on Trial

Side Effects: A Prosecutor, a Whistleblower, and a Bestselling Antidepressant on Trial
by Alison Bass (Author)


As the mental health reporter for the Boston Globe, Alison Bass's front-page reporting on conflicts of interest in medical research stunned readers, and her series on sexual misconduct among psychiatrists earned a Pulitzer Prize nomination. Now she turns her investigative skills to a controversial case that exposed the increased suicide rates among adolescents taking antidepressants such as Paxil, Prozac, and Zoloft.

Side Effects tells the tale of a gutsy assistant attorney general who, along with an unlikely whistle-blower at an Ivy League university, uncovered evidence of deception behind one of the most successful drug campaigns in history. Paxil was the world's bestselling antidepressant in 2002. Pediatric prescriptions soared, even though there was no proof that the drug...

Quitting Antidepressants the Smart Way - A step by step guide to stopping antidepressants the right way, first time

Quitting Antidepressants the Smart Way - A step by step guide to stopping antidepressants the right way, first time


Completely updated for 2014 with the latest advanced in our understanding of SSRI DiscontinuationEverything you need to know to ensure you have a "soft landing" as you come off antidepressantsA guide to getting off SSRI antidepressants and starting your drug free life again, from Benjamin Kramer, best-selling author of "Brain Renovation".In this clear and concise guide, Benjamin Kramer gives you an easy to implement blueprint for coming off antidepressants such as SSRIs (Selective Serotonin Re-uptake Inhibitors) using a variety of little-known techniques and tips.With a scientifically-designed tapering plan, including the use of certain other drugs and supplements where required, you can avoid coming in for landing too hard and crashing. Done properly, you CAN have a soft landing off...

Anti-Depressant: A Novel

Anti-Depressant: A Novel
by Patagon Press


Five brutal narratives unfold a story of obsession and redemption.

From reviews:

"Fantastic read! "

" it is a dash of B. Easton Ellis, smidge of Chuck P. even a hint of J.D. all of that and a whole lot of winding and weaving throughout a series of tangled lives. "

"...the darkest story I have ever read."

Dr. Shipko's Informed Consent for SSRI Antidepressants

Dr. Shipko's Informed Consent for SSRI Antidepressants


I am writing this eBook to share the key information that I discuss with patients in consultation before starting or stopping a serotonin reuptake inhibitor (SSRI) antidepressant. ‘Informed Consent’ is not intended to be a comprehensive book about these drugs, rather, it duplicates the information that I typically provide to my patients when I see them in consultation. If you are contemplating starting or stopping an SSRI antidepressant, then you will find this information helpful.

Mood Disorders and Antidepressants: Stahl's Essential Psychopharmacology

Mood Disorders and Antidepressants: Stahl's Essential Psychopharmacology
by Stephen M. Stahl (Author)


With the fully revised fourth edition of Essential Psychopharmacology, Dr Stahl returns to the essential roots of what it means to become a neurobiologically empowered psychopharmacologist, expertly guided in the selection and combination of treatments for individual patients in practice. This remains the essential text for all students and professionals in mental health seeking to understand and utilize current therapeutics, and to anticipate the future for novel medications. This special edition, featuring the extracted chapters on mood disorders and antidepressants, provides a readable digest on these specific issues for experts and novices alike.

© 2014 BrightSurf.com